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Background: The novel BD OnclarityTM HPV assay (Onclarity) on the BD Viper™ LT system (BD Diag-
nostics, Sparks, MD), detects E6/E7 DNA from 13 high-risk HPV genotypes and HPV66. We compared the
analytical and clinical performance of the Onclarity Assay to that of Hybrid Capture 2 and LINEAR ARRAY
using adjudicated histological outcomes from Danish women referred for colposcopy.
Methods: 276 women from Copenhagen, Denmark were referred for colposcopy with abnormal cytology
and/or a positive HPV test. Two samples for HPV analysis were taken in BD SurePath™ and in the BD cervical
brush diluent (CBD) media. ClinicalTrial gov. identiﬁer: NCT01671462, Ethical Approval: H-4-2012-070.
Results: Histology was normal in 84 (31%) women, 70 (26%) had CIN1, 47 (17%) CIN2, and 68 (25%) had CIN3.
The Onclarity assay detected 67 out of 68 (99%) ZCIN3 and 113/115 (98%) ZCIN2. The speciﬁcities for
oCIN2 were 21%, 17%, and 22%, for HC2, Onclarity and LA, respectively.
Conclusion: Overall, the Onclarity HPV assay performed well on SurePath LBC and CBD media, with clinical
sensitivity and speciﬁcity matching those of HC2 and LA.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The link between cervical cancer, the cervical cancer pre-
cursors of cervical intraepithelial neoplasia (CIN2 and CIN3), cer-
vical cancer and persistent infection with certain Human Papil-
loma Virus (HPV) genotypes is well established [1]. More than 200
genotypes are currently identiﬁed [2], of which approximately 40
can infect the mucosa of the genital tract [3], with 13 identiﬁed as
High Risk (hr) with respect to oncogenicity [4,5].
Today liquid based cytology or Pap smears constitute the
diagnostic choice for cervical screening, often with HPV testing as
reﬂex. This however will change shortly to HPV testing as the
primary choice for cervical screening given HPV DNA tests higher
sensitivity for detection of high-grade CIN and cervical cancer and
its superior quality assurance and quality controls measures as
compared to cytology [6,7].
Furthermore, in countries like Denmark systematic HPV vacci-
nated birth cohorts are entering organized screening programsB.V. This is an open access article u
ty Hospital, Department offrom 2016-17, which challenges cytology further by the sub-
stantially reduced abnormality rate because of the vaccination [8].
Together, this emphasizes the need to exchange cytology for HPV
screening within a very short timeframe.
The majority of molecular HPV assays have so far been devel-
oped based on consensus primers targeting the L1 region of the
HPV viral genome. L1 based ampliﬁcation assays have been shown
to have clinical performance compatible to the clinically validated
HC2 assay [9–12] but there are certain limitations to the use of a
consensus L1 primer approach namely the inconsistency in
detecting mixed infections of multiple genotypes. Moreover, con-
sensus assays with no or limited genotyping only allows for a lim-
ited risk stratiﬁcation of HPV positive women, most notably for
HPV16 and 18. Incidence of these genotypes is expected to be
reduced in immunized women [8,13]. Alternatively assays allowing
for genotype speciﬁc ampliﬁcation with broader genotyping cap-
ability could offer a viable alternative.
The BD Onclarity™ HPV Assay (Onclarity, BD Diagnostics, Sparks,
MD) is a novel Real Time PCR assay. The assay simultaneously
detects 13 hrHPV genotypes and HPV66 (Class 2B, possibly carci-
nogenic) [3]; provides genotyping information on six individualnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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eight HPV genotypes in three distinct groups (33/58, 56/59/66, and
35/39/68). The assay has an internal human beta globin (HBB) gene
control for sample sufﬁciency and assay performance, which is
important for laboratory quality control (QA/QC). The Onclarity
assay is the ﬁrst clinical HPV assay speciﬁcally detecting HPV DNA
E6 and E7 genes. The design includes multiple, individual real-time
PCR target ampliﬁcations [14,15]. Furthermore, by choosing non-L1
regions as the analytic target, any discussion of the argued rare L1
deleted infections can be disregarded [16,17].
This study was designed to clinically evaluate the performance
of the Onclarity assay on the fully-automated BD VIPER LT System
in a Danish population of women referred to colposcopy. We used
fresh cervical SurePath samples and samples collected in a novel
BD transport medium. The clinical performance of Onclarity was
determined relative to the well-studied Hybrid Capture 2 (HC2),
the full genotyping assay LINEAR ARRAY (LA) as well as adjudi-
cated histology.2. Material and methods
2.1. Settings
The Department of Pathology, Copenhagen University Hospital,
Hvidovre, is the largest cervical screening laboratory in Denmark,
which, annually evaluates up to 160.000 cervical SurePath samples
from women living in the Capital Region of Denmark. The laboratory
handles all cervical cytology regardless of the reason for sample-
taking. Since the 1960´s Copenhagen has been covered by an orga-
nized cervical cancer screening program [8]. The current call/recall
program targets women 23–49 year of age for screening every three
years and women aged 50-65 years of age every ﬁve years.
2.2. Sample population
276 women from the Copenhagen area referred to colposcopy
due to abnormal cytology and/or routine HPV positive samples in
concordance with national guidelines were enrolled in the study
with informed consent between December 2012 and May 2013.
Two hospitals and seven gynecologist clinics were used for
recruitment. All women meeting the study inclusion criterion
attending these sites in the recruitment period were asked for
participation. Exclusion criteria were; previous treatment for CIN;
conization, LEEP, laser surgery or cryosurgery treatment, known
pregnancy, partial or complete hysterectomy, and application of
chemical compounds to the cervix 24 hours prior to study entry.
Three womenwere excluded due to noncompliance with the study
protocol. An additional four women were excluded as the HPV
result was not available on all samples. No randomization was
conducted upon enrollment; all enrolled women received the
same diagnostic work-up. All 269 included women had four
samples taken upon gynecology examination prior to acidic acid
application to exclude any inﬂuence on subsequent analysis. A
SurePath™ liquid based cytology (LBC) and a novel cervical brush
diluent (CBD) transport medium sample followed by colposcopy
with subsequent biopsy and ECC taken. Women with negative
colposcopy had four-punch random clockwise biopsies, which is
routine practice in Denmark. The SurePath sample was used for
LBC evaluation, and the residual vial material was used for
Onclarity testing as well as LA HPV genotyping. The residual pellet
material from the SurePath LBC processing (the post-quot mate-
rial) was used for HC2 HPV testing. The CBD medium sample was
used solely for Onclarity CBD HPV testing. The age span of the
included women was 18-74, mean 32.5 years, median 30 years,
IQR 26 to 36.2.3. Cytology
Routine cytology evaluation of SurePath samples was under-
taken ﬁrst by FocalPoint™ Slide Proﬁler (BD, Burlington, NC). HPV
analysis was done after cytology evaluation; hence the cyto-
screener was blinded to the HPV result. Cytology slides were
read by cyto-screener using FocalPoint™ GS Imaging System (BD),
all ﬁndings were adjudicated by a pathologist, which had access to
the HPV result upon adjudication. Cytology was reported using the
Bethesda 2001 system. Cytology at referral was retrieved from the
Danish national PatoBank.
2.4. Histology
In the Danish screening program, women with atypical squamous
cell of undetermined signiﬁcance (ASCUS) aged Z30 years with a
positive HPV test are referred to colposcopy and biopsies, as are
women with high-grade squamous intraepithelial lesions (HSIL),
atypical squamous cells – cannot exclude HSIL (ASC-H), atypical
glandular cells (AGC) or cytological signs of carcinoma and women
with continued ASCUS and low-grade SIL (LSIL) cytological diagnoses.
All histology slides were read upfront by the same expert pathologist
(JJ). Histology was subsequently adjudicated by a pathologist from the
same laboratory (MF) and upon disagreement the slide was discussed
by the two pathologists and the agreed diagnosis was used as the
ﬁnal diagnosis. The highest adjudicated diagnosis found in either the
biopsy or ECC sample was used as the reported diagnosis. After
adjudication of all 269 samples, 12 women had a histological diag-
nosis of CIN not otherwise speciﬁed (NOS); these 12 samples were
regarded as less than CIN2 in the speciﬁcity calculations.
2.5. Hybrid Capture 2 HPV DNA testing
Hybrid Capture 2 (HC2) analysis was done on the post-quot
SurePath pellet material from the cytology procedure. HC2 is a DNA/
RNA hybridization assay detecting 13 hrHPV genotypes as a pooled
result (16, 18, 31, 33, 39, 45, 51, 52, 56, 58, 59 & 68). The post-quot
samples were denatured manually prior to HC2 analysis on the
automated Rapid Capture System (RCS) or manually according to
manufacturer’s protocol (Qiagen Gaithersburg, MD, USA). The HC2
assay has no internal control for sample sufﬁciency, but contains a
batch control for assay performance. Post-qout samples with no
visual cellular pellet upon centrifugation and a subsequent negative
HPV result after HC2 testing were reported as invalids. There was an
average of 17 days from receiving the sample to denaturation for
HC2. Samples were denatured 1–2 days before test on the RCS.
2.6. LINEAR ARRAY HPV Genotyping test
The LINEAR ARRAY (LA) is a full genotyping assay that detects
14 hrHPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 &
68, deﬁned here by us for comparison with Onclarity) and 23
potential, possible high and low risk genotypes (6, 11, 26, 40, 42, 53,
54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39, CP6108).
The assay has an internal human beta globin control for sample
sufﬁciency and assay performance. An aliquot of 0.5 ml of SurePath
residual material was spun down (14.000 rpm, 5 min), supernatant
removed and pellet resuspended in a mix of 180 μl phosphate buf-
fered saline (10x conc. pH 7.4, Pharmacy product) and 20 μl Protei-
nase K (recombinant, PCR grade, Roche Diagnostics). Samples were
subsequently vortexed and incubated one hour at 56 °C and one hour
at 90 °C. DNA was puriﬁed using MagNa Pure LC 96 (Roche Diag-
nostics, Pleasanton, CA) with MagNA Pure LC Total Nucleic Acid
Isolation Kit (Roche diagnostics). The LA included controls were
extracted using AmpliLute Liquid Media Extraction Kit (Roche Diag-
nostics). 4 ml of the puriﬁed control DNA and 12.5 μl MagnaPure
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(ﬁnal volume 50 μl). Using LINEAR ARRAY HPV genotyping test,
ampliﬁcation was performed on Biosystems Gold Plate 96 well
GeneAmp PCR system 9700. 25 μl of the PCR reaction was used for
LA testing using the LINEAR ARRAY detection kit, which was per-
formed according to manufacturer’s protocol. Hybridization strips
were read by two people for adjudication. Unfortunately the LA
package insert does not provide any information on how to read the
hybridization strips, here all bands which had the same intensity as
the lower band of internal human beta globin control was included
as positives, in addition borderline bands were included as positive if
they were part of a multiple infection.
2.7. BD Onclarity™ HPV Assay
The Cervical Brush Diluent (CBD) transport sample and an ali-
quot of the SurePath sample were used for BD Onclarity HPV test-
ing. The CBD transport sample did not require any pre-handling
before Onclarity HPV testing and was stored refrigerated or frozen
prior to testing. For the SurePath sample; 0.5 ml material was taken
from the SurePath vial prior to the SurePath cytology procedure.
The SurePath vial was vortexed vigorously and 0.5 ml was aliquoted
into a BD HPV liquid based cytology (LBC) diluent medium tube
containing 1.7 ml sample medium. The aliquoted LBC samples were
inverted 3–4 times and then stored refrigerated or frozen until
Onclarity testing on the BD Viper LT system. Prior to Onclarity
testing on the Viper platform, the samples (both LBC and CBD)
including the positive and negative controls (included in the kit)
were pre-warmed for 30 min at 120 °C on the BD pre-warm heater
station (model 443159). The pre-warmed samples were manually
loaded into the automated Viper LT platform. At the ﬁrst automated
step, the pre-warmed material was transferred to a preloaded
extraction tube that contains ferric oxide particle. A high pH is used
to lyse the cells and free the DNA into the solution, and magnets are
used to hold the bound DNA during aspiration of waste. After
washing and high pH elution, neutralization buffer is added to the
DNA to bring the pH of the extracted solution to optimal pH for PCR
ampliﬁcation. The VIPER LT instrument transfers the extracted
sample material, positive and negative controls to manually
assembled ampliﬁcation micro wells, after which real-time PCR
analysis was performed and detected by the integrated VIPER LT
reader. The assay has an internal control (human beta globin, HBB)
in each well, which provides a control for both sample and process
adequacy. The Onclarity is an E6-E7 DNA based Real Time assay that
detects 16, 18, 31, 45, 51, 52 as single genotypes and the remaining
eight genotypes in three groups (33/58, 56/59/66, 35/39/68).
2.8. Statistical analysis
HPV positive outcomes with Onclarity were deﬁned in accor-
dance with the manufacturer threshold. hrHPV genotypes by LA
were reported as the presence of one or more of the 14 detected
HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, 66 & 68) as
detected by Onclarity and non-hrHPV if one or more of the
remaining 23 potential, possible high and low risk genotypes were
present without any hrHPV infection. HC2 positive samples were
reported for those with a relative light unit per cut-off (RLU/co)
value Z1, no retest range was used. Cytology was considered
abnormal if ZASCUS was reported. The histology diagnosis CIN, not
otherwise speciﬁed (CIN NOS), was considered in the CIN1 group
for the speciﬁcity calculations. The 95% conﬁdence intervals (CI) for
sensitivity and speciﬁcity were calculated using binomial distribu-
tion. We calculated the relative speciﬁcity for CLART and HC2 by
comparing to LA and relative speciﬁcity for CLART and LA by com-
paring to HC2. The 95% CI for relative sensitivity and speciﬁcity
were calculated assuming that their algorithms were approximatelynormal distributed. Finally, we applied McNemar´s Odd Ratio to the
results as presented in Tables 2 and 3 using HC2 and LA as reference
test when compared to Onclarity LBC and CBD. Onclarity LBC was
used as reference test when compared to Onclarity CBD. HC2 was
used as a reference test when compared to LA.
2.9. Ethical approval
The study was part of a large Viper CE IVD trial (ClinicalTrial gov.
identiﬁer: NCT01671462) that had approval from the Danish Capital
Regional ethical committee, H-4-2012-070. All included women
gave signed informed consent prior to the collection of samples. All
women in the study were followed up and managed according to
Danish national guidelines, independent of the study protocol.3. Results
276 women referred to colposcopy, based on abnormal cytology
and/or positive HPV, were enrolled in the study; seven women were
excluded from the study. The majority of the included women, 257
(96%), were between 23-65 years, which is the target age of the
Danish screening program (Table 1). Of the 269 women, 68 (25%) had
normal cytology, 33 (12%) ASCUS, 31 (12%) LSIL, 9 ASC-H (3%) and 124
(46%) HSIL, 2 with cytological signs of cancer (0.7%) and 2 samples
(0,7%) had inadequate cytology. The Onclarity test results were similar
by cytology category regardless of media type. No statistical differ-
ences were observed between all three assays for cytology at referral
and cytology at colposcopy (Table 1). Onclarity testing on LBC and CBD
respectively found 234 (87%) and 240 (89%) positive samples, which
was similar to ﬁndings by HC2 (87%) and LA (85%) (Table 1).
3.1. Agreement
The overall agreement between Onclarity Assay on LBC and
HC2 was 92% (Kappa 0.639) and between Onclarity Assay on CBD
and HC2 90% (Kappa 0.539). Agreement with LA was slightly
higher, 96% to Onclarity Assay on LBC (Kappa: 0.861) and 95% to
Onclarity Assay on CBD (Kappa: 0.752) (Table 3).
The Onclarity assay detects six HPV genotypes as single results
and the remaining eight in three groups. When compared to the
genotyping of LA, including only the 14 hrHPV genotypes, the
Onclarity assay found similar amounts of HPV genotypes in each of
the Viper genotype or genotype groups (Table 2). The agreement
between Onclarity Assay LBC and LA for HPV 16, 18, 31, 45 and 51
was very good (Kappa value above 0.9). Agreement for genotype
HPV52 was still good between Onclarity and LA (Kappa value 0.863)
although the Onclarity detects HPV52 individually whereas LA
detects this genotype using a consensus primer targeting in fact four
HPV genotypes. Furthermore agreement among the three Onclarity
genotype groups and LA was good (Kappa values above 0.8). For
Onclarity Assay on LBC, 189 out of the 234 positive samples (80%),
had an identical hrHPV genotype distribution as observed by LA.
Cross reactivity to non-hrHPV genotypes for HC2 accounted for a
major proportion of the HC2 POS/Onclarity NEG samples. 9/11 HC2
POS/Onclarity LBC NEG samples reported only non-hrHPV genotypes
by LA. In Comparison 0/11 Onclarity LBC POS/HC2 NEG reported only
non-hrHPV genotypes by LA. HC2 does not detect HPV66, however
only 1/11 Onclarity LBC POS/HC2 NEG sample reported HPV56/59/66
and HPV66 only by Onclarity and LA respectively. 10/11 Onclarity LBC
POS/HC2 NEG reported hrHPV by LA. In total HC2 reported hrHPV
positive in 19 cases where LA returned a non-hrHPV only result (7%)
whereas Onclarity LBC called 3/296.
Within the 115 ZCIN2, only four samples disagreed between
Onclarity on LBC and HC2. Two Onclarity POS/HC2 NEG samples
had CIN2 diagnoses and HPV18 by LA. Two Onclarity NEG/HC2 POS
Table1
Description of the study population.
Total (column %) Onclarity LBC (row %) Onclarity CBD (row %) HC2 (row %) LA (row %)
Positive Negative Positive Negative Positive Negative Positive Low-risk only or negative
Total 269 (100%) 234 (87%) 35 (13%) 240 (89,2%) 29 (10,8%) 234 (87%) 35 (13%) 229 (85,1%) 40 (14,9%)
Age (years)
o30 127 (47.2%) 111 (87.4%) 16 (12.6%) 116 (91.3%) 11 (8.7%) 111 (87.4%) 16 (12.6%) 109 (85.8%) 18 (14.2%)
30-39 94 (34.9%) 85 (77.1%) 9 (22.9%) 84 (80.7%) 10 (19.3%) 82 (78.3%) 12 (21.7%) 85 (75.9%) 9 (24.1%)
Z40 48 (17.8%) 38 (89.1%) 10 (10.9%) 40 (95.7%) 8 (4.3%) 41 (91.3%) 7 (8.7%) 35 (89.1%) 13 (10.9%)
Cytology at referral
Normal 17 (6.3%) 15 (88.2%) 2 (11.8%) 15 (88.2%) 2 (11.8%) 13 (76.5%) 4 (23.5%) 2 (11.8%) 15 (88.2%)
ASCUS 83 (30.9%) 64 (77.1%) 19 (22.9%) 67 (80.7%) 16 (19.3%) 65 (78.3%) 18 (21.7%) 63 (75.9%) 20 (24.1%)
LSIL 46 (17.1%) 41 (89.1%) 5 (10.9%) 44 (95.7%) 2 (4.3%) 42 (91.3%) 4 (8.7%) 41 (89.1%) 5 (10.9%)
HSIlþa 123 (45.7%) 114 (92.7%) 9 (7.3%) 114 (92.7%) 9 (7.3%) 114 (92.7%) 9 (7.3%) 110 (89.4%) 13 (10.6%)
Cytology at colposcopy
Normal 68 (25.3%) 48 (70.6%) 20 (29.4%) 51 (75%) 17 (25%) 42 (61.8%) 26 (38.2%) 45 (66.2%) 23 (33.8%)
ASCUS 33 (12.3%) 29 (87.9%) 4 (12.1%) 30 (90.9%) 3 (9.1%) 30 (90.9%) 3 (9.1%) 29 (87.9%) 4 (12.1%)
LSIL 31 (11.5%) 26 (83.9%) 5 (16.1%) 26 (83.9%) 5 (16.1%) 29 (93.5%) 2 (6.5%) 26 (83.9%) 5 (16.1%)
HSILþa 135 (50.2%) 131 (97%) 4 (3%) 131 (97%) 4 (3%) 133 (98.5%) 2 (1.5%) 128 (94.8%) 7 (5.2%)
Inadequate 2 (0.7%) 0 (0%) 2 (100%) 2 (100%) 0 (0%) 0 (0%) 2 (100%) 1 (50%) 1 (50%)
Histology at Colposcopy
Normal 84 (31.2%) 59 (70.2%) 25 (29.8%) 65 (77.4%) 19 (22.6%) 58 (69%) 26 (31%) 58 (69%) 26 (31%)
CIN1 70 (26.0%) 62 (88.6%) 8 (11.4%) 63 (90%) 7 (10%) 63 (90%) 7 (10%) 61 (87.1%) 9 (12,9%)
CIN2 47 (17.5%) 46 (97.7%) 1 (21.1%) 46 (97.7%) 1 (21.1%) 45 (95.7%) 2 (4.3%) 45 (95.7%) 2 (4.3%)
CIN3 68 (25.3%) 67 (98.5%) 1 (1.5%) 66 (97.1%) 2 (2.9%) 68 (100%) 0 (0%) 65 (95.6%) 3 (4.4%)
a HSILþ: includes: HSIL, ACSH, AGC, AIS.
Table 2
HR genotype distribution of Onclarity and Linear Array.
HPV
genotype
Onclarity
LBC
Onclarity
CBD
LA LBCþ /
LAþ
LBCþ /
LA-
LBC-/
LAþ
LBC-/
LA-
Total
agreement
POS
agreement
Kappa (95% CI) Odd ratio (95%
CI)a
16 89 90 88 86 3 2 178 98.14 94.51 0.96 (0.92-
1,00)
1.5 (0.17-17.96)
P¼1.00
18 22 21 23 22 0 1 246 99.63 95.65 0.98 (0.93-
1.00)
P¼1.00b
31 48 50 42 42 6 0 221 97.77 87.50 0.92 (0.86-
0.98)
P¼0.0412b
45 26 26 29 26 0 3 240 98.88 89.66 0.94 (0.87–
1.00)
P¼0.248b
51 20 25 22 20 0 2 247 99.26 90.91 0.95 (0.88-
1.00)
P¼0.480b
52 31 32 26 25 6 1 237 97.40 78.13 0.86 (0.76-
0.96)
6.00 (0.73-276.0)
P¼0.13
33/58c 42 48 43 39 3 4 223 97.40 84.78 0.90 (0.83-
0.97)
0.75 (0.11–4.43)
P¼1.00
56/59/66c 53 53 45 42 11 3 213 94.80 75.00 0.83 (0.74-
0.91)
3.67 (0.97-20.47)
P¼0.061
35/39/68c 40 48 35 33 7 2 227 96.65 78.57 0.86 (0.77-
0.95)
3.50 (0.67-34.53)
P¼0.182
a McNemar´s odd ratio test with LA as the reference test.
b The odds ratio and its conﬁdence interval cannot be calculated because one of the discordant values is zero.
c The genotypes for LA was pooled into three groups and compared to the same groups as detected by Onclarity.
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current non-hrHPV by LA (both HPV82).
3.2. Clinical outcome and performance
Histology amongst 269 women showed 84 (31%) with normal
histology, 70 (26%) with CIN1, 47 (17%) with CIN2 and 68 (25%)
with CIN3. In total, 115 women were diagnose with ZCIN2 (43%),
and of these 68 women had (26%) ZCIN3 (see Table 4).
Onclarity Assay LBC found 113 out of 115 (Sensitivity 98%)
ZCIN2 cases and 67 out of 68 (Sensitivity: 99%) ZCIN3 cases.
Onclarity on CBD found 112 out of 115 (Sensitivity: 97%) ZCIN2
cases and 66/68 (Sensitivity: 97%) ZCIN3 cases. In comparison HC2
found 113/115 (Sensitivity: 98%) ZCIN2 cases and 68/68 (100%)
ZCIN3 cases. When limited to only the 14 HPV genotypes detected
by Onclarity, LA detected 110/115 (96%) ZCIN2 cases and 65/68 ofZCIN3 cases (96%) (See Table 4). There was no statistical difference
in sensitivity for either ZCIN2 or ZCIN3 between Onclarity Assay
and reference tests using both media types (See Table 4).
Onclarity reported 33 out of 154 negative oCIN2 samples
(speciﬁcity: 21%) and 34 out of 201 oCIN3 samples (speciﬁcity:
17%). Onclarity using the CBD medium reported 26/154 oCIN2
(speciﬁcity: 17%) and 27/201 oCIN3 (speciﬁcity: 13%). HC2
reported 33/154 oCIN2 (speciﬁcity: 21%) and 35/201 oCIN3
(speciﬁcity: 17%). LA detected 35/154 oCIN2 (speciﬁcity: 23%) and
37/201 oCIN3 (speciﬁcity: 18%) as negative or non-hrHPV only.
The CBD media induced a slight reduction in speciﬁcity for
Onclarity compared to HC2, however the difference were not
statistical signiﬁcant for either oCIN2 (relative speciﬁcity 0.79:
95% CI: 0.50-1.25) or oCIN3 (relative speciﬁcity: 0.77: 95% CI:
0.49-1.22) (Table 4).
Table 3
Overall agreement between HC2, LA and Onclarity using LBC and CBD collection material.
Assay A Assay B A POS/B POS A NEG/B NEG A POS/B NEG A NEG/B POS Total Agreement Odd ratioa
Onclarity on LBC HC2 223 24 11 11 247 (91.8%) 1,00
Kappa: 0.639 95% CI 0,39-2,54
95% CI: 0.500-0.778 P¼0,831
Onclarity on CBD 232 27 2 8 259 (96.3%) 4,00
Kappa: 0.823 95% CI 0,8-38,67
95% CI: 0.716-0.929 P¼0,114
LA 227 33 2 7 260 (96.7%) 0,29
Kappa: 0.861 95% CI 0,03-1,50
95% CI: 0.772-0.950 P¼0,182
Onclarity on CBD HC2 224 19 16 10 243 (90.3%) 1,60
Kappa: 0.539 95% CI 0,68-3,94
95% CI: 0.383-0.695 P¼0,327
LA 227 27 13 2 254 (94.4) 6,50
Kappa: 0.752 95% CI (1,47-59,33)
95% CI: 0.632-0.871 P¼0,01
HC2 LA 218 24 16 11 242 (90.0%) 0,69
Kappa: 0.582 95% CI 0,29-1,58
95% CI: 0.440-0.724 P¼0,441
a McNemar´s odd ratio test. HC2 and LA were used as reference test when compared to Onclarity LBC and CBD. Onclarity LBC was used as reference test when compared
to Onclarity CBD. HC2 was used as a reference test when compared to LA.
Table 4
Sensitivity, speciﬁcity, for HC2, Onclarity and LA.
Onclarity LBC Onclarity CBD HC2 LBC LA LBC
Endpoint ZCIN2
Sensitivity (95% CI) 0.98 (0.94-1.0) 0.97 (0.93-1.0) 0.98 (0.94-1.00) 0.96 (0.90-0.99)
Relative Sensitivity vs. HC2 1.0 (0.97-1.03) 0.99 (0.95-1.03) 1.0 0.97 (0.93-1.02)
Speciﬁcity 0.21 (0.15-0.29) 0.17 (0.11–0.24) 0.21 (0.15-0.29) 0.23 (0.16–0.30)
Relative speciﬁcity vs. HC2 1.0 (0.65-1.53) 0.79 (0.50-1.25) 1.0 1.06 (0.70-1.61)
Endpoint ZCIN3
Sensitivity (95% CI) 0.99 (0.92-1.0) 0.97 (0.90-1.0) 1.0 (0.95-1.0) 0.96 (0.88-0.99)
Relative Sensitivity vs. HC2 0.99 (0.96-1.01) 0.97 (0.93-1.01) 1.0 0.96 (0.91-1.01)
Speciﬁcity 0.17 (0.12-0.23) 0.13 (0.12-0.23) 0.17 (0.12-0.23) 0.18 (0.13-0.25)
Relative speciﬁcity vs. HC2 0.97 (0.63-1.49) 0.77 (0.49-1.22) 1.0 1.06 (0.70-1.61)
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4.1. General ﬁndings
The aim of the current study was to evaluate the BD Onclarity™
HPV Assay against HC2 for clinical and analytical performance and
Linear Array for analytical genotyping performance. Moreover, this
is one of ﬁrst systematic reports on HPV assay performance
comparison on SurePath™™ referral samples. Finally, we eval-
uated the Onclarity performance on a novel cervical brush trans-
port medium on samples taken in parallel with a regular SurePath
sample. All 269 samples taken at colposcopy in the two media
types were tested on Onclarity, HC2 and LA and compared to
adjudicated histology. HPV positive ﬁndings by Onclarity on LBC
samples were 234 out of 269 specimens and using the CBD
medium 240 out of 269 specimens. This was similar to what was
observed using HC2 (234/269) and LA (229/269).
The Onclarity assay is a hrHPV assay with extended genotyping.
The value of genotyping is increasingly utilized in clinical screening
to risk stratify women based upon the HPV genotype detected. Most
recently, the US interim guidelines calls for differential follow up of
HPV16 or 18 positive samples [18], and a number of European
countries use a similar approach. The genotype dependent risk
stratiﬁcation is founded on the widely recognized knowledge that
the 13 hrHPV genotypes overall differs substantially in their onco-
genic potential [4,5,19–21]. By utilizing this knowledge differential
follow up algorithms can be employed however this requires that
the assay used entails genotyping.The overall concordance on LBC samples between Onclarity and
HC2 or LAwas found to be substantial or almost perfect (92%, Kappa:
0.639, 95%, kappa: 0.861), respectively. When comparing genotype
detection of Onclarity and LA on LBC samples, agreement was sub-
stantial for HPV 16, 18, 31, 45 and 51 (kappa values above 0.9), and
despite HPV52 being a cross reactive probe for LA [22,23] the
agreement was substantial (Kappa value: 0.863). Similar con-
cordances were observed for samples taken in the CBD medium
(Table 3). Specimens that tested negative on HC2 but positive on
Onclarity were more likely to be positive for hrHPV by LA, whereas
HC2 positive and Onclarity negative were more likely to be non-
hrHPV by LA. This is in line with previously reported ﬁndings [24].
Cross reactivity to non-hrHPV genotypes by HC2 has previously been
described in detail on STM stored samples [25–28]. Here 19 out 269
(7%) samples testing positive on HC2 but with non-hrHPV genotypes
only by LA (including HPV66). In comparison, only 3 of 269 samples
reported Onclarity LBC positive/ LA non-hrHPV (excluding HPV66).
Observed discrepancy between Onclarity and HC2 could therefore be
attributed to HC2 cross reactivity to non-hrHPV genotypes.
The sensitivity of Onclarity for ZCIN2 and ZCIN3 on both LBC
and CBD mediumwere found to be similar to that of HC2 (Table 4).
In addition, the speciﬁcity for Onclarity on LBC matched that of
HC2 and LA. The CBD medium induced a slight reduction in spe-
ciﬁcity for Onclarity, but the difference was not statistically sig-
niﬁcant (Table 4).
In this setting an hrHPV positive sample was deﬁned by the 14
HPV genotypes detected by Onclarity. Though HPV66 is not deﬁned
by IARC as hrHPV genotype, it was included as a hrHPV genotype in
D.M. Ejegod et al. / Papillomavirus Research 2 (2016) 31–3736this analysis. For concordance analysis, the same deﬁnition of
hrHPV was used to evaluate concordance with LA. Eight LA samples
were HPV66 positive, and all were diagnosed with oCIN2. The
speciﬁcity for 4CIN2 for LA was 28% excluding HPV66 as a hrHPV.
Hardly surprising, these data indicate that in this particular popu-
lation the addition of HPV66 as a hrHPV genotype does not provide
additional sensitivity for disease.
4.2. Comparison to the literature
The Onclarity Assay has previously been described using ThinPrep
and STM samples [9,10,14,15,24,25,29]. In the Predictor 2 study [10]
ThinPrep samples from women with abnormal cytology was used to
evaluate seven HPV assays including also the previous conﬁguration of
the Onclarity Assay. The study reported similar prevalence for
Onclarity (82%) and HC2 (86%) in womenwith abnormal cytology and
concordant clinical performances for Onclarity and HC2 (sensitivity:
95%, speciﬁcity: 24% and sensitivity: 96%, speciﬁcity: 20%, respectively)
for ZCIN2 [10]. Agreement between Onclarity and HC2 was high
(90%) and clinical sensitivity for Onclarity was 94%, with a speciﬁcity of
26% [29]. Finally, a recent study performed on archived SurePath
samples tested on the Viper LT system with Onclarity showed clinical
performances comparable to our results [24].
Overall, Onclarity performs similar to HC2 in ThinPrep and Sur-
ePath stored samples on multiple referral patient cohorts. Onclarity
brings the added clinical information of genotyping to the table
compared to the “positive/negative” result of HC2. One element
stands out in our study compared to previous publications in that
our test material were fresh samples from a routine work ﬂow. All
samples here were sent to one laboratory and tested by the same
routine staff thereby minimizing any potential laboratory-to-
laboratory performance variability. Moreover, our routine diag-
nostic procedures requires that LA strips were read by two persons
for adjudication and the subsequent genotype comparison between
the Onclarity and LA were performed on mutually detected geno-
types only. Finally, where the majority of studies focused on Thin-
Prep stored samples, we evaluated the performance on SurePath
stored samples as well as on a novel virus transport medium taken
in parallel. This study provides important performance data on
SurePath stored samples not previously reported for the Onclarity
HPV assay. However the weakness of our study is that using only
referral population samples, true primary screening performance
cannot be assessed in this study design. This has recently been
reported for ThinpPrep stored samples through the Predictor
3 study the Onclarity Assay [9], however a similar study has not yet
been performed on SurePath samples.
4.3. Conclusion
Onclarity performed well on SurePath and on the new novel
cervical brush transport medium samples from women referred to
colposcopy. Clinical performance was similar to that of HC2. On
prospective collected samples, the Onclarity Assay had equal high
sensitivity and speciﬁcity for ZCIN2 and ZCIN3 compared to HC2,
but with the added power of extended hrHPV genotyping con-
cordant to that of LA. Finally, the Onclarity is fully automated for
ease of use. Overall, the BD Onclarity HPV Assay is a strong HPV
candidate for use in clinical cervical cancer screening pending fur-
ther studies ongoing to validate its clinical performance also outside
the high prevalence referral population used here.Competing interests
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